Abstract 767P
Background
Radiotherapy is linked to neurocognitive sequelae in brain tumor patients. This prospective randomized study (CTRI/2024/06/069040) evaluates the impact of radiotherapy on neurocognitive function in grade 2-3 gliomas post-surgery and pre-adjuvant radiotherapy, focusing on various neurocognitive domains and their correlations with demographic and pathological variables. Understanding these deficits and identifying associated factors is crucial to optimize patient care and outcomes.
Methods
We analyzed baseline data from 80 patients enrolled in the ongoing trial. Eligible patients had histologically proven grade 2-3 gliomas, were aged 18-60 years, with an MMSE score above 18 and required adjuvant therapy,. Prior to radiotherapy planning, they underwent MMSE, Montreal Cognitive Assessment (MOCA), and PGI Memory Scale (PGIMS) assessments. Descriptive and correlation statistics characterized demographic details and explored associations between neurocognitive dysfunction and clinicopathological factors.
Results
The cohort had a slight male preponderance (1.13:1) with a mean age of 39 years (20-60). Predominant tumor types were oligodendroglioma (ODG) grade 3 (37.5%) and ODG grade 2 (35%), mainly located in the frontal (43.8%) and frontotemporal (22.5%) lobes. Mean MMSE and MOCA scores were 26.1 (IQR 23-29) and 21.8 (IQR 18-25). Significant impairments were observed in memory domains: attention/concentration (67.5%), delayed recall (67.5%), and verbal retention for dissimilar pairs (50%). Age and literacy showed a negative correlation (p < 0.001), while no significant correlations were found between cognitive function and histology, grade, extent of surgical resection, tumor laterality, or location.
Conclusions
This study highlights the prevalence of neurocognitive impairments in postoperative patients with grade 2 and 3 gliomas, especially in memory functions, even in those deemed functionally intact on MMSE. Demographic factors such as age and literacy significantly influence cognitive outcomes. These findings underscore the importance of baseline neurocognitive assessment and may guide specific interventions to improve patients’ quality of life and functional outcomes during and after adjuvant therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.